During the past decade, Michigan CardioVascular Institute conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 9 clinical trials were completed, i.e. on average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Michigan CardioVascular Institute" #1 sponsor was "Abbott Medical Devices" with 3 trials, followed by "Boston Scientific Corporation" with 2 trials sponsored, "Juventas Therapeutics, Inc." with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Anesiva, Inc." with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Michigan CardioVascular Institute" #1 collaborator was "Baim Institute for Clinical Research" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "California Institute for Regenerative Medicine (CIRM)" with 1 trials as a collaborator, "Daiichi Sankyo, Inc." with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Michigan CardioVascular Institute" are "Coronary Artery Disease" (4 trials), "Heart Failure" (4 trials), "Cardiovascular Disease" (3 trials), "Myocardial Infarction" (3 trials) and "Congestive Heart Failure" (2 trials). Many other conditions were trialed in "Michigan CardioVascular Institute" in a lesser frequency.

Most popular intervention types in "Michigan CardioVascular Institute" are "Device" (10 trials), "Drug" (10 trials), "Biological" (4 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "bococizumab (PF-04950615)" (2 trials), "Autologous cell therapy" (1 trials), "BAROSTIM NEO System and Medical Management" (1 trials) and "BiV/MPP" (1 trials). Other intervention names were less common.

The vast majority of trials in "Michigan CardioVascular Institute" are 24 trials for "All" genders.

Currently, there are NaN active trials in "Michigan CardioVascular Institute". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Michigan CardioVascular Institute, 1 suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Michigan CardioVascular Institute, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 3 trials that are defined as “Not Applicable".